Single Nucleotide Polymorphism in Gene Encoding Transcription Factor Prep1 Is Associated with HIV-1-Associated Dementia

Sebastiaan M. Bol1,3, Thijs Booiman1*, Daniëlle van Manen1, Evelien M. Bunnik1, Ard I. van Sighem2, Margit Sieberer1, Brigitte Boeser-Nunnink1, Frank de Wolf2,3, Hanneke Schuitemaker1, Peter Portegies4,5, Neeltje A. Kootstra1, Angélique B. van ‘t Wout1*

1 Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory and Center for Infection and Immunity Amsterdam (CINIMA) at the Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands, 2 HIV Monitoring Foundation, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands, 3 Department of Infectious Disease Epidemiology, Imperial College, London, United Kingdom, 4 Department of Neurology at the Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands, 5 Department of Neurology at the OLVG Hospital, Amsterdam, The Netherlands

Abstract

Background: Infection with HIV-1 may result in severe cognitive and motor impairment, referred to as HIV-1-associated dementia (HAD). While its prevalence has dropped significantly in the era of combination antiretroviral therapy, milder neurocognitive disorders persist with a high prevalence. To identify additional therapeutic targets for treating HIV-associated neurocognitive disorders, several candidate gene polymorphisms have been evaluated, but few have been replicated across multiple studies.

Methods: We here tested 7 candidate gene polymorphisms for association with HAD in a case-control study consisting of 86 HAD cases and 246 non-HAD AIDS patients as controls. Since infected monocytes and macrophages are thought to play an important role in the infection of the brain, 5 recently identified single nucleotide polymorphisms (SNPs) affecting HIV-1 replication in macrophages in vitro were also tested.

Results: The CCR5 wt/Δ32 genotype was only associated with HAD in individuals who developed AIDS prior to 1991, in agreement with the observed fading effect of this genotype on viral load set point. A significant difference in genotype distribution among all cases and controls irrespective of year of AIDS diagnosis was found only for a SNP in candidate gene PREP1 (p = 1.2 × 10⁻²). Prep1 has recently been identified as a transcription factor preferentially binding the –2,518 G allele in the promoter of the gene encoding MCP-1, a protein with a well established role in the etiology of HAD.

Conclusion: These results support previous findings suggesting an important role for MCP-1 in the onset of HIV-1-associated neurocognitive disorders.

Introduction

While the prevalence of HIV-1-associated dementia (HAD) has greatly decreased, first with the introduction of zidovudine [1,2] and later with combination antiretroviral therapy (cART) [3,4], neurocognitive impairment is still seen more frequently in HIV-1-infected patients than in seronegative individuals. In recent years a new terminology has been developed to classify this broadening clinical spectrum of neurocognitive impairment, including milder abnormalities. HAND (HIV-1-associated neurocognitive disorders) is the umbrella definition, comprising three entities: asymptomatic neurocognitive impairment, mild neurocognitive disorders (MND), and HAD. Clinical symptoms of HAND are cognitive impairment (memory, concentration), motor dysfunction and behavioral changes. Recent studies showed that MND occurred in 15–50% of the HIV-1-infected individuals [5–9], and HAD in 1–10% of the patients [4,5,7,8].

Although CD4+ T cells are the predominant cell type infected by HIV-1 and primarily associated with the disease course, circulating monocytes as well as macrophages can also become infected and contribute to the viral reservoir and disease progression [10]. Furthermore, monocytes and macrophages play a crucial role in certain HIV-1-related pathologies, including HAND [10]. Despite lack of strong evidence it is generally believed that HIV-1 migrates across the blood-brain barrier in monocytes that were infected in the blood [11,12]. Indeed, in the
brain, the monocyte-derived perivascular macrophages and microglia are the most commonly HIV-1-infected cells [13,14]. Complex mechanisms underlie the neurodegeneration, since neurons themselves are not infected by HIV-1. Local production of HIV-1 proteins [15–18] or other non-HIV compounds [19–24] by infected and activated macrophages and microglia cause neuronal damage. Furthermore, neuronal injury may occur as a consequence of the inflammatory process in the brain [25–27].

As is the case for many complex disorders, it remains unclear why some individuals are more at risk to develop HAND than others. The cause of the neurodegeneration is multi-factorial, and in addition to viral genetic factors [28–30], host genetic predisposition may also contribute to the susceptibility to these disorders. We previously reported a reduced prevalence of the 32 base pair deletion in the CCR5 gene in HIV-infected individuals with HAD as compared to controls with AIDS but no HAD [31], and recently a single nucleotide polymorphism (SNP) in the gene of one of its natural ligands, CCL3, was identified to be associated with HAD as well [32]. SNPs in MCP-1 (monocyte chemoattractant protein-1) and TNFα were found to affect protein expression levels of these genes [33–36] and were associated with the onset of HAD [34,37,38]. A biological mechanism by which the SNP in MCP-1, located at position −2,518 in the promoter region, affects gene expression was described recently [39]. This study demonstrated that the transcription factor Prep1 preferentially binds the −2,518 G allele in MCP-1, thereby affecting transcription of this protein. Furthermore a SNP in CCR2, encoding the receptor for MCP-1, was associated with rate of progression to neuropsychological impairment [40]. However, few of the associations between polymorphisms and HAD have been replicated in other studies (see Table 1 for an overview of all identified associations between host common genetic variants and HAD).

Here, we evaluated the polymorphisms in previously tested candidate genes CCR5, CCR2, MCP-1, TNFα, APOE and CCL3, as well as a polymorphism in the novel candidate gene PREP1, for their association with HAD in participants of the Amsterdam Cohort Studies of HIV infection and AIDS (ACS) and the AIDS therapy evaluation in The Netherlands (ATHENA) observational cohort. In addition, given the important role of monocytes and macrophages in the etiology of HAD, SNPs that we recently identified to affect HIV-1 replication in macrophages in vitro were also tested [41].

Materials and Methods

Ethics statement

This study has been conducted in accordance with the ethical principles set out in the declaration of Helsinki. Anonymized archival material (peripheral blood mononuclear cells or DNA) from AIDS patients was used in this study, which was approved by the Medical Ethics Committee of the Academic Medical Center in Amsterdam, The Netherlands. For the qPCR experiments, anonymized buffy coat or full blood was used from healthy blood donors, and the use was approved by the Medical Ethics Committee of the Academic Medical Center and the Ethics Advisory Body of the Sanquin Blood Supply Foundation in Amsterdam, The Netherlands. Written informed consent was obtained from all of these healthy donors.

Study population

In total we selected 86 AIDS patients with HAD (cases) from the Amsterdam Cohort Studies and ATHENA observational cohort from whom DNA was available for genotyping. Before the AIDS dementia complex was defined as a distinct clinical syndrome the diagnosis of dementia in these patients had been based on DSM-III (Diagnostic and Statistical Manual of Mental Disorders) criteria. Motor abnormalities were present in all these demented patients, which agreed retrospectively with the diagnostic criteria of the AIDS dementia complex [42]. When more precise

| Gene | Polymorphism | Association with HAND | No association with HAND |
|------|--------------|-----------------------|-------------------------|
| APOE | E4 isof orm  | Corder et al. [60], HAD; prospective cohort study (n = 44) | Pemberton et al. [61], HAD; 56 cases, 112 controls |
|      |              |                       | Diaz-Arrastia et al. [62], HIVE; cohort A: 43 cases and 104 controls, and cohort B: 14 cases and 117 controls |
|      |              |                       | Dunlop et al. [63], HAD and HIVE; 32 HAD cases, 24 possible HAD cases and 73 controls |
| CCL3 | rs1130371    | Levine et al. [32], HAD; 26 cases, 117 controls | Van Rij et al. [31], HAD; 49 cases, 186 controls |
| CCR2 | rs1799864 V64I | Singh et al. [40], HAND, prospective cohort study (n = 123) | |
| CCR5 | Δ32          | Van Rij et al. [31], HAD; 49 cases, 186 controls | Singh et al. [40], HAND, prospective cohort study (n = 121) |
| MCP-1 | rs1024611 (~−2518 A>G) | Gonzalez et al. [34], HAD; prospective cohort study (n = 1,115) | Singh et al. [40], HAND, prospective cohort study (n = 121) |
|      |              | Shiramizu et al. [37], HIV-1 DNA in CSF; 27 specimens | Levine et al. [32], HAD; 26 cases, 117 controls |
| TNFα | rs1800629 (~−308 G>A) | Quasney et al. [38], HAD; 16 cases, 45 controls | Sato-Matsumura et al. [64], HIVE; 44 cases, 30 controls |
|      |              | Pemberton et al. [61], HAD; 56 cases, 112 controls | Levine et al. [32], HAD; 26 cases, 117 controls |
|      |              | Diaz-Arrastia et al. [62], HIVE; cohort A: 43 cases and 104 controls, and cohort B: 14 cases and 117 controls |
diagnostic criteria were introduced in 1991 and 2007 ([43,44]), these criteria were used to classify these patients. The absence of dementia was confirmed by neurological examination by a neurologist.

We compared the HAD patients with 246 AIDS patients without HAD (controls) (Table 2). A subset of these samples (49 cases and 186 controls) was included in a previous study that investigated CCR5Δ32 and CCR2V64I genotype frequencies between HAD cases and controls [31].

Cases and controls were matched for year of AIDS diagnosis (AIDS diagnosis was based on AIDS defining events according to the CDC AIDS definition 1987; Kaposi’s sarcoma was excluded as an AIDS defining event), time from AIDS diagnosis to death or to start of combination antiretroviral therapy (cART), age at AIDS diagnosis and CD4+ T cell count at AIDS diagnosis. Cases receiving cART more than 6 months before their HAD diagnosis (n = 14), as well as controls who started cART more than 6 months before their AIDS diagnosis (n = 5) were excluded from the analysis. Median time from AIDS to developing HAD for the cases was significantly shorter than the time from AIDS to death or to start cART in the control population (p<0.0001; Mann Whitney test) (Table 2), indicating that time from AIDS to death or to start cART for the HIV-1-infected individuals in the control group was in principle long enough to develop HAD. Similar results were obtained when using Kaplan-Meier analysis, with no difference in time from AIDS to death (start cART used as censor) and significant shorter time from AIDS to HAD for the cases, than time from AIDS to death (start cART as censor) for the controls (p = 0.00036, logrank test) (Figure 1A–B). Information on ancestry was only known for a limited number of patients and was based on reported ethnicity by the treating physician or reported country of birth.

Candidate SNP selection and genotyping

Genotype distributions of polymorphisms previously associated with HAND (Table 1) as well as SNPs associated with in vitro HIV-1 replication in macrophages (cutoff p value = 5 × 10−5) (Table S1) [41], were analyzed in this case-control study. PREP1

![Table 2. Characteristics of the studied population consisting of AIDS patients with or without HAD.](image)

Table 2. Characteristics of the studied population consisting of AIDS patients with or without HAD.

| Characteristics                                      | HAD patients | Non-HAD patients | p       |
|------------------------------------------------------|--------------|------------------|---------|
|                                                      | (cases, n = 72) | (controls, n = 241) |         |
| AIDS diagnosis (year); median (range)                | 1989 (1984–2005) n = 69 | 1990 (1985–2005) n = 241 | –       |
| Time AIDS to death or start cART (months); median (range) | 14 (0–114) n = 67 | 12 (0–81) n = 234 | 0.211 |
| Time AIDS to HAD (months); median (range)            | 5 (0–114) n = 69 | N.A.              | <0.00011.2 |
| Age at diagnosis AIDS; average (range)               | 40 (22–63) n = 69 | 41 (23–71) n = 241 | 0.603 |
| CD4+ T cell count (cells/μl) at AIDS, median (range)³ | 120 (10–850) n = 39 | 105 (7–1,380) n = 166 | 0.48³ |
| Mode of HIV-1 transmission (IDU : other)             | 4 : 35       | 4 : 158          | 0.048³ |

N.A., not applicable; HAD, HIV-1-associated dementia; IDU, injecting drug user.

¹Mann Whitney test.
²Time to develop HAD after AIDS diagnosis among the cases was compared to the time from AIDS diagnosis to death or to start cART in the control group.
³Unpaired t test.
⁴CD4+ T cell counts within 6 months to the date of AIDS diagnosis.
⁵Fisher’s exact test.

doi:10.1371/journal.pone.0030990.t002

![Figure 1. Comparison of AIDS survival between HAD cases and non-HAD controls.](image)

Figure 1. Comparison of AIDS survival between HAD cases and non-HAD controls. (A) Kaplan Meier analysis for time from AIDS to death with start cART as censor (vertical lines), for both HAD cases (grey line) and non-HAD AIDS patients as controls (black line). (B) Kaplan Meier analysis for time from AIDS to death with start cART as censor (vertical lines) for the controls (black line) and for time from AIDS to HAD for the HAD cases (grey line). cART, combination antiretroviral therapy; HAD, HIV-1-associated dementia.

doi:10.1371/journal.pone.0030990.g001
was selected because of its preferred binding to the −2,518 G allele in the promoter region of MCP-1. SNP rs2839619 was selected from 17 SNPs in PREP1 after preliminary analysis comparing 15 cases with 126 unmatch controls. This SNP seems of particular interest since it was shown to be associated with cholesterol metabolism [45], which is known to play a role in the etiology of Alzheimer’s disease [46] and, in addition, is in linkage disequilibrium ( \( r^2 = 0.51 \) ) with nearby intronic SNP rs234720 that has been associated with cognitive test performance [47].

Peripheral blood mononuclear cells were used for isolation of genomic DNA using QIAamp DNA blood mini kit (Qiagen, Valencia, CA, USA) or NucleoSpin blood kit (Macherey-Nagel, Düren, Germany). SNP genotypes for SNPs in DYRK1A, PDE8A, UBR7 and PREP1 (Table S1) were available for 172 individuals (18 cases, 154 controls) from a recent study on the effects of host genetic variation on HIV-1 susceptibility and disease progression [48]. For the remaining DNA samples and other SNPs not present on the Illuma SNP beadchip, ABI TaqMan® SNP genotyping assays (Applied Biosystems, Carlsbad, CA, USA) were used for genotyping (Table S1). For all SNPs except the SNP in TNFA, genotyping assays were run on a LightCycler® 480 system (Roche, Basel, Switzerland) using Probes Master (Roche) with the following amplification cycles: 10 min 95°C; 50 cycles of 15 sec 95°C, 1 min 60°C.

The TNF-4 SNP assay was run on an Applied Biosystems 7500 Fast-Real-Time PCR System (Applied Biosystems) with Taqman genotyping master mix (Applied Biosystems), and using the following amplification cycles: 10 min 95°C; 40 cycles of 15 sec 95°C, 1 min 60°C. APOE allele types (E2, E3 or E4 [49]) were determined by genotyping SNPs rs1299582 (C or T) and rs7412 (C or T). CCR5 Δ32 and CCR2 V64I genotyping was performed as described previously [50,51].

Quantitative PCR

Buffy coat or full blood was obtained from 69 healthy blood donors. Monocyte isolation and monocyte-derived macrophage (MDM) culture was performed as previously described [52]. Total RNA was extracted from day 7 uninfected MDM using the High Pure RNA Isolation kit (Roche). Oligo(dT) primers were used for reverse transcription of mRNA, using Roche’s Transcriptor First Strand cDNA Synthesis kit (60 min at 50°C). Resulting cDNA was used for quantitative PCR (qPCR) analysis, using the following primers: PREP1 F and R, MCP-1 F and R, and GAPDH F and R (Table S2). qPCRs were performed with SYBR Green I Master (Roche) and were run on a LightCycler® 480 system (Roche) using the following amplification cycles: 10 min 95°C; 50 cycles of 10 sec 95°C, 20 sec 60°C, 30 sec 72°C. All procedures were carried out according to manufacturer’s protocol. Messenger RNA expression is reported relative to GAPDH. Gene expression values were obtained using Roche’s LightCycler® relative quantification software (release 1.5.0). To facilitate accurate and reliable between-donor comparison, cDNA synthesis and qPCR experiments for all 69 samples were performed simultaneously.

Statistical analysis

Fisher’s exact test was used to test for differences in SNP genotype distribution between cases and controls. To test for differences in group characteristics between cases and controls the Mann Whitney test and the unpaired t test were used. One-way ANOVA was performed to test for differences in mRNA levels between genotypes. Statistical analysis was performed using the statistical computing software R (version 2.9.0) and GraphPad Prism (version 3).

Results

Genotype frequencies for all polymorphisms tested, in the group of cases with HAD (n = 72) and the group of controls that did not develop HAD (n = 241), are displayed in Table 3. Of the 12 polymorphisms tested, a significant difference in genotype distribution for SNP rs2839619 in PREP1 was found between cases and controls (\( p = 1.2 \times 10^{-5} \); 71 cases and 235 controls; DNA was limited for some of the cases or controls, therefore not all samples could always be genotyped). The difference remained statistically significant after Bonferroni correction for multiple comparisons (n = 12), p = 1.4 × 10−4. Also after excluding HAD

| Table 3. Genotype distribution among HAD (cases) and non-HAD (controls) HIV-1-infected patients for all polymorphisms tested. |
|---|---|---|---|---|---|---|
| Gene | Polymorphism | Cases (HAD) | | | | |
| | | AA | AB | BB | AA | AB | BB | p |
| APOE | E4 isoform 2 | 52 | 16 | 1 | 158 | 52 | 5 | 0.95 |
| CCL3 | rs1130371 | 40 | 26 | 5 | 133 | 90 | 9 | 0.53 |
| CCR2 | rs1799864 (V64I) | 64 | 8 | 0 | 206 | 34 | 1 | 0.66 |
| CCR5 | Δ32 | 66 | 6 | 0 | 203 | 38 | 0 | 0.13 |
| DYNK1A | rs12483205 | 38 | 25 | 8 | 125 | 96 | 11 | 0.13 |
| MCP-1 | G | 3 | 27 | 41 | 14 | 101 | 116 | 0.58 |
| MOAP1 | rs1046099 | 29 | 36 | 6 | 117 | 93 | 20 | 0.28 |
| PDE8A | rs12090130 | 33 | 34 | 4 | 110 | 96 | 26 | 0.34 |
| PREP1 | rs2839619 | 30 | 17 | 24 | 55 | 130 | 50 | 1.2 × 10^{-6} |
| SPOCK3 | rs17519417 | 21 | 32 | 17 | 76 | 102 | 53 | 0.91 |
| TNFA | rs1800629 (−308 G>A) | 57 | 13 | 1 | 158 | 62 | 9 | 0.20 |
| UBR7 | rs2905 | 10 | 28 | 33 | 22 | 107 | 103 | 0.42 |

1Polymorphisms selected from earlier studies that tested for association between genotype and HAD.

2In the case of APOE AA, AB and BB refer to no APOE E4, one APOE E4 allele and two APOE E4 alleles, respectively.

3SNPs selected from a previous study that found associations between these SNPs and HIV-1 replication in macrophages.

*Significant difference after correction for multiple testing (n = 12); Bonferroni threshold p = 4.2 × 10−3.

doi:10.1371/journal.pone.0030990.t003
cases with known non-Caucasian ethnicity, or for whom injecting drug use was reported as mode of HIV-1 transmission, a known risk factor for HAD [4], the difference in PREP1 SNP genotype distribution between cases (n = 64) and controls remained significant (n = 211) \( p = 4.3 \times 10^{-3} \). Quantitative PCR experiments performed to investigate if the SNP in PREP1 was associated with either PREP1 or MCP-1 mRNA levels showed no difference in PREP1 or MCP-1 mRNA levels between the three PREP1 SNP genotypes \( p = 0.3 \) and 0.8, respectively, \( n = 69 \); one way ANOVA (data not shown).

Remarkably, for none of the other polymorphisms tested, including those previously reported to be associated with HAD (CCR5 Δ32, promoter SNP in MCP-1, the −308 G>A SNP in TNFA, CCR2 V64I variant, Apo E4 isoform and a SNP in CCL5), a significant difference was found in genotype distribution between cases and controls. In a previous case-control study [31], we described a reduced prevalence of the CCR5 wt/Δ32 genotype among HAD patients. A subset of cases and controls from this published study overlaps with our current study population. Cases and controls that were additionally included for this study seroconverted on average later in time. We recently reported that in the HIV-1 epidemic in The Netherlands, the impact of certain host factor polymorphisms, including CCR5 Δ32, might be fading [33]. We therefore hypothesized that the protective impact of the CCR5 wt/Δ32 genotype on the onset of HAD also may have decreased over time. To test this hypothesis we divided cases and controls into two groups using the median year of AIDS diagnosis of the complete study population (1990). This approach was chosen over using seroconversion date since this information was unavailable for 29 of 42 cases with AIDS diagnosis ≤1990. Importantly, cases and controls with AIDS diagnosis >1990 matched all of the characteristics as described above (Table S4), and time from AIDS to death or to start cART for the HIV-1-infected individuals in the control group was in principle long enough to develop HAD \( p = 0.005 \) and \( p = 0.001 \) for cases and controls with AIDS diagnosis ≤1990 and >1990, respectively, Mann Whitney test) (Table S4). Similar results were obtained when using Kaplan-Meier analysis and logrank test (data not shown). When the CCR5 wt/Δ32 genotype frequency was compared between cases and controls we observed a difference in the “AIDS diagnosis ≤1990” group \( p = 0.046 \), but not for the “AIDS diagnosis >1990” group \( p = 1.00 \) (Table S3), indeed suggestive of a fading protective effect. Assuming that other genetic effects may also have diminished over time in our cohort, we performed the same analysis for the remaining polymorphisms (Table S3). For 9 polymorphisms, no significant associations were observed in either group. The effect of the SNP in PREP1 was clearly independent of the year of AIDS diagnosis, since in both groups there were significantly fewer heterozygous individuals for SNP rs2839619 among cases than controls \( p = 0.001 \) and \( p = 0.008 \) for the “AIDS diagnosis ≤1990” and the “AIDS diagnosis >1990 group”, respectively) (Table S3). Conversely, a significant (defined as \( p<0.05 \); however not significant after correction for multiple testing, \( n = 24 \)) association with HAD was observed for the SNP in DYRK1A only in the group with AIDS diagnosis after 1990.

Discussion

Here we describe the first combined evaluation of all previously identified genetic polymorphisms reported to be associated with the prevalence of HAND. In addition, we evaluated polymorphisms that we recently identified to be associated with HIV-1 replication in macrophages for their association with HAD. For one of the 12 polymorphisms tested, SNP rs2839619 in PREP1, we observed a significantly different genotype distribution when comparing AIDS patients with and without HAD. The prevalence of the heterozygous genotype was 55% among controls (and 53% in the HapMap CEU population, \( n = 226 \)), as compared to only 24% among HAD cases, suggesting that the heterozygous genotype has a protective effect against the development of HAD (positive heterosis). Although multiple examples of heterosis exist ([54,55] and reviewed in [56]), the molecular basis for this heterozygous effect sometimes remains difficult to understand (reviewed in [56,57]).

Case-control studies are greatly influenced by variation in allele frequency across different subgroups [58] that may lead to identification of false positive associations. However, the association for the PREP1 SNP remained significant after excluding patients expected to be of non-European descent. Moreover, since the allele frequency for this SNP is similar for Caucasians, Asians and Africans (NCBI dbSNP) we do not expect that additional population stratification resulting from ethnicity would affect this association. Differences in population substructure may be of importance when SNP rs2839619 is not the causal variant but rather tags another genetic variant, since for that particular SNP genotype distributions may vary between different populations. In addition, the outcome remained unaffected after correcting for injecting drug use as mode of HIV-1 transmission. Although it is known that Prep1 binds to the promoter region of MCP-1, we were unable to demonstrate an association between SNP genotype and MCP-1 mRNA levels in MDM. However, MCP-1 is secreted by monocytes and macrophages, but expression is not limited to these cell-types. The cytokine is also expressed in for HAD possibly more relevant cells such as endothelial cells, astrocytes, microglia and neurons ([59] and references therein). Functional follow-up studies will need to delineate a mechanism that helps to explain the observed reduced frequency of heterozygous donors in the group of HAD patients.

None of the previously identified associations between genetic variants and HAND could be replicated in our present study, even when tested under a dominant or recessive model (data not shown). Many of the candidate gene polymorphisms suggested to play a role in the prevalence of HAND have not been reproduced widely in other cohorts (Table 1). Limitations in the availability of patient material, heterogeneity in HAND diagnoses, differences in case-control matching strategies and possible population substructure may have contributed to the absence of robust and replicable results. While we tried to carefully address many of these issues in this study, no robust replication of the reported associations was obtained, suggesting that meta-analyses of multiple HAND cohorts may be required to reliably evaluate the effect of host polymorphisms on HAND.

SNPs previously associated with HIV-1 Gag p24 levels in macrophage cultures were not found to be associated with HAD, although meta-analyses may be required to firmly establish this. This possibly suggests that the quantity of HIV-1 replication in macrophages is less important for the etiology of this phenotype as compared to the immune activation in the brain as a consequence of HIV-1 replication [12].

The protective effect observed for the CCR5 wt/Δ32 genotype was only observed in the group of individuals that had an AIDS diagnosis ≤1990 and no longer in the group that was diagnosed with AIDS >1990. Excluding cases and control from non-European descent, in whom the CCR5 wt/Δ32 genotype is less frequent, did not change the outcome of the analysis. In agreement with these findings, we observed a similar fading impact of the
The association of a SNP in PREP1 with the onset of HAD further supports the biological importance of MCP-1 in the pathogenesis of this disease. Replication of this association in an independent cohort using matched HAD cases and controls will now be highly desirable. Functional studies will be required to delineate how the observed difference in allele frequencies can be explained in a biological context.

Supporting Information

Table S1 Overview of SNPs genotyped using the ABI TaqMan® SNP genotyping.

Table S2 Overview of primers used for qPCR experiments.

Table S3 Overview of genotype distribution comparisons between HAD cases and controls with AIDS diagnosis before or after 1991.

Table S4 Characteristics of HIV-1-positive patients with or without HAD, divided in a groups with AIDS diagnosis before or after 1991.

Acknowledgments

The authors are indebted to all participants of the Amsterdam Cohort Studies and the ATHENA observational cohort. We thank Judith Schouten for critical reading of the manuscript and Michiel van der Vlist for help with SNP genotyping.

The Amsterdam Cohort Studies on HIV infection and AIDS, a collaboration between the Public Health Service of Amsterdam, the Academic Medical Center of the University of Amsterdam, the Sanquin Blood Supply Foundation, Jan van Goyen Medical Center, and the University Medical Center Utrecht, are part of the Netherlands HIV Monitoring Foundation and financially supported by the Center for Infectious Disease Control of the Netherlands National Institute for Public Health and the Environment.

Patient recruitment at the Netherlands HIV Treatment Centers has been made possible through the collaborative efforts of the following physicians (*site coordinating physicians):

Academisch Medisch Centrum bij de Universiteit van Amsterdam: Prof. Dr. JM Prins*, Prof. dr. TW Kuijpers, Dr. HJ Scherpier, Dr. K. Boer, Dr. JTM van der Meer, Dr. FWMN Wit, Dr. MH Godfried, Prof. dr. P. Reiss, Prof. Dr. T van der Poll, Dr. FJB Nellen, Prof. dr. JMA Lange, Dr. SE Geerlings, Dr. M van Vugt, Drs. SME Vrouenraets, Drs. D. Pajkrt, Drs. JC Bos, Drs. M van der Valk.

Academisch Ziekenhuis Maastricht, Maastricht: Dr. G. Schreij*, Dr. S. Lowie, Dr. A. Oude Lashof. Catharina-ziekenhuis, Eindhoven: Drs. MJH Pronk*, Dr. B Brauwenhoer. Erasmus Medisch Centrum, Rotterdam: Dr. ME van der Ende*, Drs. TEMS de Vries-Shuijs, Dr. CAM Schurink, Drs. M. van der Feltz, Dr. J. Nolwenn, Dr. LBS Gelinck, Dr. A. Verbon, Drs. BJA Rijnders, Drs. E. van de Veen-de Ruiter, Dr. L. Slobo. HagaZiekenhuis, Den Haag: Dr. RH Kauffman*, Dr. EF Schippers. Isala Kliniken, Zwolle: Dr. PHJ Groeneveld*, Dr. MA Allemann, Drs. JW Bouwhuis. Kennemner Gasthuis, Haarlem: Prof. dr. RW ten Kate*, Dr. R. Soetkouw. Leids Universitair Medisch Centrum, Leiden: Prof. dr. J.P. den Bruijn, Dr. EP Kroon*, Prof. dr. PJ van den Dolder, Dr. JT van Duijzen, Dr. SM Arends, Drs. C van Nieuwkoop, Drs. MGJ de Boer, Drs. H. Jolink. Maasstadziekenhuizen, Rotterdam: Dr. JG den Hollander*, Dr. K. Pogony. Medisch Centrum Alkmaar, Alkmaar: Dr. W. Bronsweld*, Dr. W. Kortmann, Drs. G. van Twillert. Medisch Centrum Leeuwarden, Leeuwarden: Drs. DPF van Hout*, Dr. MB Polec, Dr. MGA van Volendern. Medisch Spectrum Twente, Enschede: Drs. ON der Velden, Drs. CH de Haan, Drs. MA Scholvink, Drs. J. van Assen, CJ Stiek. Medisch Centrum Maastricht, Maastricht: Dr. PHJ Frits, Drs. WEM Schouten, Drs. GEL van den Berk. Sint Elisabeth Ziekenhuis, Tilburg: Dr. J.T. Juttmann*, Dr. MEE van Kasteren, Drs. AE Brouwer. Slotervaart Ziekenhuis, Amsterdam: Dr. JW Mulder*, Dr. ECM van Gorp, Drs. PM Smit, Weijer. Stichting Medisch Centrum Jan van Goyen, Amsterdam: Drs. A van Eeden*, Dr. DWM Verhagen*, Universitair Medisch Centrum Groningen, Groningen: Dr. HG Sprenger*, Dr. RG Doede, Dr. EH Scholvink, Drs. S van Assen, CJ Stiek. Universitair Medisch Centrum Utrecht: Prof. Dr. IM Hoepelman*, Dr. TM Mourikova, Dr. MME Schneider, Drs. CAJJ Jaspers, Dr. PM Ellerbrock, Dr. EJJ Peters, Dr. LJ Maarschalk-Ellerbrock, Dr. JJ Oosterheert, Dr. JE Arends, Dr. MWM Wassenberg, Dr. JCJ van der Hilst. Ziekenhuis Rijnstate, Arnhem: Dr. C. Richter*, Dr. JP van der Berg, Dr. EH Gisolf.

The authors are indebted to the trial nurses at each site for providing logistic support.

Author Contributions

Conceived and designed the experiments: ABW SMB. Performed the experiments: SMB TB NAK ABW. Analyzed the data: SMB TB DVM AVS. Contributed reagents/materials/analysis tools: FDW PP HS NAK ABW. Wrote the paper: SMB TB NAK ABW.

References

1. Vago L, Castagna A, Lazzarin A, Trabattoni G, Cinque P, et al. (1993) Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine. J Acquir Immune Defic Syndr 6: 42–45.
2. Portegies P, Eting RH, De Gans J, Algra PR, Derix MM, et al. (1993) Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 7: 669–675.
3. d’Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, et al. (2004) Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55: 320–328.
4. Bhaskaran K, Mussini C, Antonini A, Walker AS, Dorril M, et al. (2000) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 56: 213–221.
5. Simonis S, Cavassini M, Ammon JM, Kimberlin AA, Bourquin I, et al. (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24: 1243–1250.
6. Vivithanaporn P, Heo G, Gamble J, Kentz Z, Hoke A, et al. (2010) Neurologic disease burden in treated HIV/AIDS: Predicts survival: a population-based study. Neurology 74: 1130–1138.
7. Heaton RK, Clifford DB, Franklin Jr. DR, Woods SP, Ace C, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 73: 2087–2096.
8. Hareluk J, Buchhalz S, Taylor M, Schäff G, Zhong J, et al. (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS.
9. Schouten J, Cinque P, Gislen M, Reiss P, Portegies P (2010) HIV-1 infection and cognitive impairment in the ART-CARE: a review. AIDS 24: 621–632.
10. Bel SM, Cobo JL, Jiménez V, Köroitz NA, Van’t Wout AE (2011) HIV-1 and the macrophage. Future Virology 6: 187–200.
11. Peluso R, Haase A, Stowering L, Edwards M, Ventura P (1985) A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology 147: 231–236.
12. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69–81.
13. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MB (1986) Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83: 7089–7093.
14. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, et al. (1996) Localization of HIV-1 in human brain using polymerase chain reaction in situ hybridization and immunocytochemistry. Ann Neurol 39: 755–761.
15. Pillaim L, West D, Haigwood N, Swanson RA (1993) HIV-1 envelope gp120 alters astrocytes in human brain cultures. AIDS Res Hum Retroviruses 9: 429–444.
16. Munoz-Domingo DS, Knudsen BE, Greger JD, Browstone RM, Nath A (1995) Human immunodeficiency virus type 1 Tat activates non-N-Methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol 35: 373–390.
17. Kaul M, Lipton SA (1999) Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 96: 8212–8216.
18. Patel CA, Mukhtar H, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74: 9177–9176.
19. Grein P, Jett M, Bernstein EW, Boyle T, Gelbard HA, et al. (1999) Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med 186: 1703–1718.
20. Achim CL, Heyes MP, Wiley CA (1993) Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest 91: 2769–2777.
21. Schindlmayrera H, Notte HS, Swindells S, Jett M, Dzenko KA, et al. (1994) Platelet-activating factor is a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 68: 4620–4635.
22. Bukinsky MI, Notte HS, Schindlmayrera H, Dubrovsky L, Flanagan CR, et al. (1995) Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med 181: 735–745.
23. Jiang ZG, Piggie C, Heyes MP, Murphy C, Querry B, et al. (2001) Glutamate is a mediator of neurotoxicity in secretions of activated HIV-1-infected macrophages. J Neuroimmunol 117: 97–103.
24. Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995) Immunocytochemical expression of human immunodeficiency virus type 1 in the brain: correlations with dementia. Ann Neurol 38: 755–762.
25. Schindlmayrera H, Notte HS, Nusso G, Raeder T, Flanagan CR, et al. (1996) Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A 93: 709–714.
26. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
27. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
28. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
29. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
30. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
31. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
32. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
33. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
34. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
35. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
36. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
37. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
38. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
39. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
40. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
41. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
42. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.
43. Seilhean D, Kobayashi K, He Y, Uchihara T, Rosenblum O, et al. (1997) Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to progression to SI virus virus viremia. Proc Natl Acad Sci U S A 94: 7701–7706.